GSK plc (LON:GSK) Receives GBX 1,917.86 Consensus Price Target from Analysts

Shares of GSK plc (LON:GSK) have earned a consensus rating of “Hold” from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is GBX 1,917.86.

GSK has been the topic of a number of analyst reports. UBS Group reaffirmed a “neutral” rating and set a GBX 1,940 price objective on shares of GSK in a report on Friday, January 23rd. Deutsche Bank Aktiengesellschaft increased their target price on shares of GSK from GBX 1,600 to GBX 1,675 and gave the company a “hold” rating in a report on Thursday, January 15th. Citigroup boosted their price target on shares of GSK from GBX 1,900 to GBX 2,250 and gave the stock a “buy” rating in a report on Monday, February 9th. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 2,100 price objective on shares of GSK in a research report on Wednesday, January 7th. Finally, Berenberg Bank increased their price objective on shares of GSK from GBX 1,600 to GBX 1,660 and gave the company a “hold” rating in a research note on Monday, November 24th.

GSK Stock Performance

Shares of GSK opened at GBX 2,029 on Friday. The firm has a market capitalization of £81.39 billion, a P/E ratio of 14.62, a P/E/G ratio of 1.24 and a beta of 0.32. GSK has a 52 week low of GBX 1,242.50 and a 52 week high of GBX 2,282. The stock has a 50 day moving average price of GBX 2,017.71 and a two-hundred day moving average price of GBX 1,802.68. The company has a debt-to-equity ratio of 108.20, a quick ratio of 0.73 and a current ratio of 0.82.

GSK (LON:GSK) last announced its earnings results on Wednesday, February 4th. The company reported GBX 172 earnings per share (EPS) for the quarter. GSK had a return on equity of 37.19% and a net margin of 17.50%. Equities analysts forecast that GSK will post 175.980975 earnings per share for the current fiscal year.

Insider Activity at GSK

In other GSK news, insider Jonathan Symonds acquired 2,500 shares of GSK stock in a transaction on Thursday, February 5th. The stock was purchased at an average price of GBX 2,114 per share, for a total transaction of £52,850. Also, insider Luke Miels sold 15,579 shares of the firm’s stock in a transaction on Friday, February 13th. The shares were sold at an average price of GBX 2,160, for a total value of £336,506.40. Over the last three months, insiders acquired 7,931 shares of company stock valued at $16,480,489. 0.26% of the stock is owned by insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.